

# Contents

## Parti

<b>1 Introduction to the Handbook of Bioentrepreneurship.....</b>	<b>1</b>
Holger Patzelt and Thomas Brenner	
References.....	6
<b>2 Biotechnology Dynamics at the Global Scale.....</b>	<b>7</b>
Philip Cooke	
2.1 Introduction.....	7
2.2 The Global Health Care Market in Relation to Biotechnology.....	9
2.3 Global Bioregions.....	13
2.4 The World Leaders in Brief: Top Bioclusters in the USA.....	15
2.5 Comparison of UK and German Clusters.....	19
2.6 Bioregions and Their Key Characteristics.Elsewhere.....	23
2.6.1 Economic Geography of Clusters Spawned by Pharmaceuticals Firms.....	24
2.6.2 The Research and DBF-led Clusters;in Israel and Canada.....	28
2.7 Conclusions.....	31
References.....	32
<b>3 Geographic Clustering in Biotechnology: Social Networks and Firm Foundings.....</b>	<b>35</b>
Dirk Fornahl and Olav Sorenson	
3.1 Introduction.....	35
3.2 Social Networks-and Geographic Proximity.....	38
3.3 Social Networks and.Entrepreneurship.....	40
3.3.1 Opportunity Perception.....	40
3.3.2 Intellectual Capital.....	42
3.3.3 Human Capital.....	43
3.3.4 Financial Capital.....	44
3.4 Implications and Evidence.....	45
3.5 Policy Implications.....	47
3.6 Summary and Outlook.....	48
References;.....	49

<b>4 Innovation Networks in Biotechnology.....</b>	<b>53</b>
Pier Paolo Saviotti and David Catherine	
4.1 Introduction.....	53
4.2 The Nature of Innovation Networks.....	55
4.2.1 The Entry of New Firms.....	55
4.2.2 Biotechnology.....	56
4.2.3 The Changing Role of Universities.....	57
4.2.4 Theories of Industrial Organization.....	59
4.2.5 Innovation Networks.....	60
4.3 Recent Developments in Network Dynamics.....	68
4.4 Summary and Conclusions.....	76
References.....	78

**Part II**

<b>5 Strategy and Strategic Thinking in Biotechnology Entrepreneurship.....</b>	<b>83</b>
Alan L. Carsrud, Malin Brannback and Maija Renko	
5.1 Introduction.....	83
5.2 Sector Development Review.....	85
5.3 Innovation in Biotechnology.....	88
5.4 Theoretical Bases for Entrepreneurial Biotechnology.....	90
<sup>1</sup> 5.5 Strategic Management, Entrepreneurship, and Biotechnology.....	91
5.6 Strategy Components in Early-Stage Biotechnology Firms.....	93
5.6.1 Proactiveness.....	93
5.6.2 Fit.....	94
5.6.3 Reactiveness.....	96
5.6.4 Traditions and History..... <sup>1</sup>	96
5.7 Discussion and Conclusions.....	97
References.....	99

<b>6 Research on Strategic Alliances in Biotechnology: An Assessment and Review.....</b>	<b>105</b>
Maxim Sytch and Philipp Bubenzer	
6.1 Introduction.....	105
6.2 Why and with Whom Do Biotechnology Firms Form Alliances?.....	107
6.2.1 Access to Knowledge and Other Complementary Resources.....	108
6.2.2 Pursuit of Legitimacy.....	109
6.2.3 Choosing Partners.....	110
6.3 Governance of Alliances.....	111
6.4 Consequences of Alliances.....	115
6.4.1 Consequences of Accessing Knowledge and Other Complementary Resources.....	116
6.4.2 Consequences of Enhancing Legitimacy.....	120
6.4.3 Taking Off the Rose-Colored Glasses: Alliances as Relational Liability.....	121
6.5 Future Research.....	124
References.....	126

<b>7 Mergers and Acquisitions in the Biotechnology Industry.....</b>	<b>133</b>
Lars Schweizer and Dodo zu Knyphausen-Aufsess	
7.1 Introduction.....	133
7.2 Development of the Biotechnology Industry and the Need for M&A.....	134
7.2.1 The Development of the Biotechnology Industry from a Scientific Perspective.....	134
7.2.2 The Development of the Biotechnology Industry from an Organizational Perspective.....	135
7.2.3 The Development of the Biotechnology Industry from a Financial Perspective.....	137
7.3 Layers of M&A Activities.....	138
7.3.1 M&A Activities Among Biotechnology Companies.....	138
7.3.2 M&A Activities Between Pharmaceutical and Biotechnology Companies.....	141
7.4 Summary and Future Research.....	144
References.....	145

<b>8 Synergy, Strategy and Serendipity: Kirin Brewery's Entry into Biopharmaceuticals.....</b>	<b>149</b>
Michael J. Lynskey	
8.1 Introduction.....	149
8.2 The Locus of Entrepreneurship.....	150
8.3 Background.....	151
8.4 Synergy.....	152
8.4.1 Opportunity Recognition.....	155
8.4.2 Early Efforts with Erythropoietin.....	155
8.4.3 Importance of Tacit Knowledge.....	156
8.4.4 Scientific Gatekeepers and Academic Collaboration.....	157
8.5 Serendipity.....	159
8.5.1 Origins of the Alliance with, Amgen.....	160
8.5.2 Structure of the Joint Venture.....	162
8.5.3 Kirin's Contributions and Manufacturing Scale-Up.....	163
8.5.4 Outcome of the Joint Venture.....	164
8.5.5 Key Success Factors.....	165
8.6 Strategy.....	167
8.6.1 Targeting Niche Therapeutic Fields.....	167
8.6.2 Cell Therapy and Stem Cell Research.....	168
8.6.3 Monoclonal Antibodies and the Transgenic Mouse.....	169
8.7 Conclusions.....	172
References.....	174

### Part III

<b>9 A Survey Review of University Biotechnology and Entrepreneurship Commercialization.....</b>	<b>179</b>
David B. Audretsch, T. Taylor Aldridge and Marcus Perry	
9.1 Introduction.....	179

9.2 Commercialization of Science and Entrepreneurial Choice.....	180
9.3 Scientist Biotech Entrepreneurship.....	183'
9.4 Conclusions.....	188
References.....	189
<b>10 University-Based Biotechnology Spin-Offs.....</b>	<b>193</b>
Amalya L. Oliver	
10.1 Introduction.....	193
10.1.1 The Context of the Biotechnology Industry.....	193
10.1.2 Entrepreneurial Universities.....	194
10.2 Scientific Entrepreneurship.....	196
10.2.1 Changes in Academic Science.....	196
10.3 University Spin-Offs and University-Based Spin-Offs.....	198
10.3.1 University-Based Spin-Offs as a New Organizational Form. . . .	199
10.3.2 Levels of Analysis of USOs and USBOs.....	200
10.3.3 A Life Cycle Approach to USOs.....	205
10.4 Integration, Complexities and New Research Directions.....	205
References.....	207
<b>Part IV</b>	
<b>11 Patenting Biotechnology.....</b>	<b>211</b>
Saradindu Bhaduri	
11.1 Introduction.....	211
11.2 Biotechnology Industry: Meaning and Scope.....	214
11.2.1 Genetic Engineering: Basic Features.....	214
11.2.2 Genetic Engineering: Continuity or Discontinuity?.....	215
11.3 Patents: An Overview.....	216
11.3.1 Basic Issues.....	216
11.3.2 Evolution of Patents in Biotechnology.....	220
11.4 Patenting Biotechnology: Implications.....	222
11.4.1 Patenting Life Forms and 'Ordre Public': Basic Issues and Inter-country Comparison.....	222
11.4.2 Implications of Patent Length.....	224
11.4.3 Implications of Patent Scope.....	225
11.4.4 Benefit Sharing: 'Bio-Diversity' vis-a-vis 'Indigenous Science' ..	238
11.5 Conclusion.....	240
References.....	241
<b>12 Legal Frameworks and Public Support in the Biotechnology Industry ..</b>	<b>249</b>
Dirk Engel and Oliver Heneric	
12.1 Introduction.....	249
12.2 Legal Framework and Public Support: Rationales and Economic Relevance.....	250
12.2.1 Rationales for Public Support and a Legal Framework.....	250
12.2.2 The Impact of Public R&D Funding: Empirical Findings.....	252
12.2.3 Evidence Concerning the Impact of Legal Framework Changes...257	

12.3 Legal Framework Changes in Germany.....	258
12.4 An Empirical Assessment of the Contribution of Legal Framework Change.....	266
12.5 Future Research and Concluding Remarks.....	271
References.....	272
<b>Index.....</b>	<b>275</b>